Cargando…

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare, aggressive T‐cell malignancy. Chemotherapy alone cures only 25‐45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic bloo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaramillo, Sonia, Hennemann, Hannah, Horak, Peter, Teleanu, Veronica, Heilig, Christoph E., Hutter, Barbara, Stenzinger, Albrecht, Glimm, Hanno, Goeppert, Benjamin, Müller‐Tidow, Carsten, Fröhling, Stefan, Schönland, Stefan, Schlenk, Richard F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175749/ https://www.ncbi.nlm.nih.gov/pubmed/35846099 http://dx.doi.org/10.1002/jha2.143

Ejemplares similares

Community-driven development of a modified progression-free survival ratio for precision oncology
por: Mock, Andreas, et al.
Publicado: (2019)

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
por: Horak, Peter, et al.
Publicado: (2016)

Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
por: Simon, Malte, et al.
Publicado: (2022)

Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
por: Simon, Malte, et al.
Publicado: (2021)

Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing
por: Mc Connell, Lauren, et al.
Publicado: (2020)

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
por: Gröschel, Stefan, et al.
Publicado: (2016)

Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling
por: Teleanu, Maria‐Veronica, et al.
Publicado: (2023)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
por: Mock, Andreas, et al.
Publicado: (2023)

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
por: Heilig, C.E., et al.
Publicado: (2021)

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards
por: Perera-Bel, Júlia, et al.
Publicado: (2018)

Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards
por: Rieke, Damian T., et al.
Publicado: (2022)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
por: Horak, Peter, et al.
Publicado: (2019)

The landscape of chromothripsis across adult cancer types
por: Voronina, Natalia, et al.
Publicado: (2020)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
por: Gröschel, Stefan, et al.
Publicado: (2019)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity
por: Möhrmann, Lino, et al.
Publicado: (2022)

Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2020)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
por: Dittrich, Tobias, et al.
Publicado: (2022)

Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia
por: Horak, Peter, et al.
Publicado: (2020)

Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia
por: Horak, Peter, et al.
Publicado: (2021)

Accurate and efficient detection of gene fusions from RNA sequencing data
por: Uhrig, Sebastian, et al.
Publicado: (2021)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera
por: Swei, Eric C., et al.
Publicado: (2022)

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease
por: Levy, Ofer, et al.
Publicado: (2022)

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2020)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

Letter in response to the case report “Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis”
por: Teklu, Meron, et al.
Publicado: (2023)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

TelomereHunter – in silico estimation of telomere content and composition from cancer genomes
por: Feuerbach, Lars, et al.
Publicado: (2019)

Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
por: Jaramillo, Sonia, et al.
Publicado: (2021)

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n3iahip8ajhsfvssiraufvbovp